Dopamine antagonists and the development of breast cancer

Archives of General Psychiatry

Volumn 59, Issue 12, 2002, Pages 1147-1154

  Wang, Philip S ^a,b   Walker, Alexander M ^b   Tsuang, Ming T ^b,c   Orav, E John ^a   Glynn, Robert J ^a   Levin, Raisa ^a   Avorn, Jerry ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETOPHENAZINE DIMALEATE; ANTIEMETIC AGENT; CHLORPROMAZINE; CLOZAPINE; DOPAMINE RECEPTOR BLOCKING AGENT; FLUPHENAZINE; HALOPERIDOL; LOXAPINE; MESORIDAZINE; METOCLOPRAMIDE; MOLINDONE; PERPHENAZINE; PIMOZIDE; PROCHLORPERAZINE; PROLACTIN; PROMAZINE; RISPERIDONE; THIORIDAZINE; TIOTIXENE; TRIFLUOPERAZINE;

ADULT; AGED; ARTICLE; BREAST CANCER; CALCULATION; CANCER INCIDENCE; CANCER REGISTRY; CANCER RISK; COHORT ANALYSIS; COLON CANCER; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DOSE RESPONSE; DRUG EXPOSURE; DRUG USE; FEMALE; HAZARD; HUMAN; MAJOR CLINICAL STUDY; MENTAL DISEASE; MODEL; RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; BREAST NEOPLASMS; COHORT STUDIES; CROSS-SECTIONAL STUDIES; DOPAMINE ANTAGONISTS; FEMALE; HUMANS; MIDDLE AGED; NEW JERSEY; PROLACTIN; PROPORTIONAL HAZARDS MODELS; PSYCHOTIC DISORDERS; RETROSPECTIVE STUDIES; RISK;

EID: 0036897032     PISSN: 0003990X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archpsyc.59.12.1147     Document Type: Article

References (47)

1. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1997. CA Cancer J Clin. 1997;47:5-27.
2. Dickson RA, Glazer WM. Neuroleptic-induced hyperprolactinemia. Schizophr Res. 1999;35(suppl):S75-S86.
3. Schyve PM, Smithline F, Meltzer HY. Neuroleptic-induced prolactin level elevation and breast cancer. Arch Gen Psychiatry. 1978;35:1291-1301.
4. Welsch CW, Nagasawa H. Prolactin and murine mammary tumorigenesis: A review. Cancer Res. 1977;37:951-963.
5. Duncan KL, Don BR, Schaeffer LD. An introductory study of the influence and role of prolactin in mammary tumor growth. Proc West Pharmacol Soc. 1977; 20:195-197.
6. Pearson OH, Llerena O, Llerena L. Prolactin-dependent rat mammary cancer: A model for man? Trans Assoc Am Physicians. 1969;82:225-238.
7. Forrest DA. Introduction: Prolactin, the pituitary and breast cancer. In: Boyns AR, Griffiths K, eds. Fourth Tenovus Workshop on Prolactin and Carcinogenesis. Cardiff, Wales: Alpha Omega Alpha Publishing; 1972:124-127.
8. Katz J, Kunofsky S, Patton RE, Allaway NC. Cancer mortality among patients in New York mental hospitals. Cancer. 1967;20:2194-2199.
9. Costa D, Mestes E, Coban A. Breast and other cancer deaths in a mental hospital. Neoplasma. 1981;28:371-378.
10. Baldwin JA, Schizophrenia and physical disease. Psychol Med. 1979;9:611-618.
11. Tsuang MT, Woolson R, Fleming JA. Schizophrenia and cancer death. Lancet. 1980;1:480-481.
12. Fox BH, Howell MA. Cancer risk among psychiatric patients: A hypothesis. Int J Epidemiol. 1974;3:207-208.
13. Halbreich U, Shen J, Panaro V. Are chronic psychiatric patients at increased risk for developing breast cancer? Am J Psychiatry. 1996;153:559-560.
14. Goodwin PJ. Breast cancer risk in psychiatric patients [letter]. Am J Psychiatry. 1997;154:588.
15. Torrey EF. Breast cancer risk in psychiatric patients [letter]. Am J Psychiatry. 1997;154:588-589.
16. Mortensen PB. Breast cancer risk in psychiatric patients [letter]. Am J Psychiatry. 1997;154:589.
17. Gulbinat W, Dupont A, Jablensky A, Jensen OM, Marsella A, Nakane Y, Sartorius N. Cancer incidence of schizophrenic patients: Results of record linkage studies in three countries. Br J Psychiatry. 1992;161(suppl 18):75-85.
18. Goode DJ, Corbett WT, Schey HM, Suh SH, Woodie B, Morris DL, Morrisey L. Breast cancer in hospitalized psychiatric patients. Am J Psychiatry. 1981;138:804-806.
19. Kanhouwa S, Gowdy JM, Solomon JD. Phenothiazines and breast cancer. J Natl Med Assoc. 1984;76:785-788.
20. Overall JE. Prior psychiatric treatment and the development of breast cancer. Arch Gen Psychiatry. 1978;35:898-899.
21. Ettigi P, Lal S, Friesen HG. Prolactin, phenothiazines, admission to mental hospital, and carcinoma of the breast. Lancet. 1973;2:266-267.
22. Wagner S, Mantel N. Breast cancer at a psychiatric hospital before and after the introduction of neuroleptic agents. Cancer Res. 1978;38:2703-2708.
23. Thompson WD, Weissman MM. Breast cancer and treatment with neuroleptics. Arch Gen Psychiatry. 1979;36:604-605.
24. Mortensen PB. Neuroleptic treatment and other factors modifying cancer risk in schizophrenic patients. Acta Psychiatr Scand. 1987;75:585-590.
25. Mortensen PB. The occurrence of cancer in first admitted schizophrenic patients. Schizophr Res. 1994;12:185-194.
26. Adler LE, Griffith JM. Concurrent medical illness in the schizophrenic patient: Epidemiology, diagnosis, and management. Schizophr Res. 1991;4:91-107.
27. Redelmeier DA, Tan SH, Booth GL. The treatment of unrelated disorders in patients with chronic medical diseases. N Engl J Med. 1998;338:1516-1520.
28. Druss BG, Bradford DW, Rosenheck RA, Radford MJ, Krumholz HM. Mental disorders and use of cardiovascular procedures after myocardial infarction. JAMA. 2000;283:506-511.
29. Derogatis LR, Feldstein M, Morrow G, Schmale A, Schmitt M, Gates C, Murawski B, Holland J, Penman D, Melisaratos N, Enelow AJ, Adler LM. A survey of psychotropic drug prescriptions in an oncology population. Cancer. 1979;44:1919-1929.
30. Collett JP, Boivin JF, Spitzer WO. Bias and confounding in pharmacoepidemiology. In: Strom BL, ed. Pharmacoepidemiology. 2nd Ed. Chichester, England: John Wiley & Sons Ltd; 1994.
31. International Classification of Diseases, 9th Revision, Clinical Modification. Washington, DC: Public Health Service, US Dept of Health and Human Services; 1988.
32. Physicians' Current Procedural Terminology, 4th Edition. Chicago, III: American Medical Association; 1989.
33. St Anthony's Diagnosis Related Group Working Guidebook. Alexandria, Va: St Anthony Publishing; 1993.
34. Ayanian JZ, Kohler BA, Abe T, Epstein AM. The relation between health insurance coverage and clinical outcomes among women with breast cancer. N Engl J Med. 1993;329:326-331.
35. Lehman AF, Steinwachs DM. Translating research into practice: The Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. Schizophr Bull. 1998;24:1-10.
36. Wang PS, Walker AM, Tsuang MT, Orav EJ, Levin R, Avorn J. Finding incident breast cancer cases through US claims data and a state cancer registry. Cancer Causes Control. 2001;12:257-265.
37. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis. 1987;40:373-383.
38. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613-619.
39. SAS Release 6.12 [Computer Program]. Cary, NC: SAS Institute Inc; 1996.
40. Kelsey JL. Breast cancer epidemiology. Epidemiol Rev. 1993;15:256-263.
41. Kelsey JL, Horn-Ross P. Breast cancer: Magnitude of the problem and descriptive epidemiology. Epidemiol Rev. 1993;15:7-16.
42. Krieger N. Social class and the black/white cross-over in the age-specific incidence of breast cancer: A study linking census-derived data to population based registry records. Am J Epidemiol. 1990;131:804-814.
43. Bodian CA. Benign breast diseases, carcinoma in situ, and breast cancer risk. Epidemiol Rev. 1993;15:177-187.
44. Hunter DJ, Willett WC. Diet, body size and breast cancer. Epidemiol Rev. 1993; 15:110-132.
45. Horn-Ross PL. Multiple primary cancers involving the breast. Epidemiol Rev. 1993; 15:169-176.
46. Cohen SM, Ellwein LB. Cell proliferation in carcinogenesis. Science. 1990;249:1007-1011.
47. Ames BN. Mutagenesis and carcinogenesis: Endogenous and exogenous factors. Environ Mol Mutagen. 1989;14(suppl 16):66-77.